Zacks Research Upgrades Alterity Therapeutics (NASDAQ:ATHE) to Hold

Alterity Therapeutics (NASDAQ:ATHE) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

ATHE has been the subject of several other reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, January 21st. Canaccord Genuity Group began coverage on Alterity Therapeutics in a research note on Wednesday, December 17th. They issued a “speculative buy” rating for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold”.

Alterity Therapeutics Price Performance

Shares of ATHE opened at $3.49 on Thursday. Alterity Therapeutics has a 1-year low of $2.52 and a 1-year high of $7.00. The firm has a fifty day moving average price of $3.27 and a 200 day moving average price of $4.05.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of ATHE. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics during the third quarter worth $220,000. Twin Lakes Capital Management LLC raised its position in Alterity Therapeutics by 2,250.3% during the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock worth $524,000 after buying an additional 133,333 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics in the 3rd quarter worth $83,000. Finally, Greenleaf Trust boosted its holdings in shares of Alterity Therapeutics by 88.2% in the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after acquiring an additional 15,000 shares in the last quarter. 2.14% of the stock is currently owned by hedge funds and other institutional investors.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.